Johnson & Johnson (JNJ) stock
Health Care · Pharmaceuticals
Johnson & Johnson (JNJ) is a Pharmaceuticals company in the Health Care sector, headquartered in New Brunswick, New Jersey. As of October 23, 2026, JNJ closed at $263.81, a market capitalization of $635.07 billion, the 18th largest company in the S&P 500. Over the last twelve months it generated $99.33 billion in revenue (+6% year over year) and $22.23 billion in free cash flow. The stock trades at 40.0x trailing earnings and 22.7x forward earnings.
- 1-year total return: +40.2% (dividends reinvested)
- 5-year return: +13.1% a year
- 52-week range: $184.66 – $281.07
- Gross margin 67.8%, operating margin 25.7%
- Dividend yield: 2.03%, 61 straight years of increases
- FI Handbook report card: B- across 10 metrics
- 2nd largest of 60 Health Care stocks in the S&P 500
JNJ price chart
1Y price change: +37.1% (price only; total returns below include dividends)
| Total return | 1M | YTD | 1Y | 3Y | 5Y | 10Y | MAX |
|---|---|---|---|---|---|---|---|
| JNJ | -2.0% | +29.5% | +40.2% | +23.8% | +13.1% | +11.8% | +13.8% |
Dividends reinvested. 3Y and longer are annualized; MAX is annualized since 1962.
JNJ key statistics
- Market cap
- $635.1B
- #18 in S&P 500
- P/E (TTM)
- 40.0x
- Forward P/E
- 22.7x
- EPS (TTM)
- $6.59
- Revenue (TTM)
- $99.3B
- +6%
- Free cash flow
- $22.2B
- Gross margin
- 67.8%
- Operating margin
- 25.7%
- Return on equity
- 20.0%
- Dividend yield
- 2.03%
- 52-week range
- $184.66 – $281.07
- Beta
- 0.21
- Price / sales
- 6.4x
- EV / EBITDA
- 19.2x
- Debt / equity
- 0.55x
- Employees
- 138,200
JNJ report card
B-Ten fundamentals graded A to F against fixed thresholds. Not a buy or sell rating.
- Revenue growth5.9%C
- Gross margin67.8%A
- Operating margin25.7%B
- FCF margin22.4%B
- Return on equity20.0%B
- Net debt / EBITDA0.8xB
- Forward P/E22.7xC
- PEG ratio2.8xD
- Shareholder yield3.0%C
- Share count change / yr-2.0%B
Johnson & Johnson financials
Revenue went from $74.3B in fiscal 2014 to $94.2B in fiscal 2025, growing 2.2% a year.
| Fiscal year | 2014 | 2016 | 2017 | 2018 | 2019 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $74.3B | $70.1B | $76.5B | $81.6B | $82.1B | $82.6B | $78.7B | $85.2B | $88.8B | $94.2B |
| Gross profit | $51.6B | $48.5B | $51.0B | $54.5B | $54.5B | $54.2B | $55.3B | $58.6B | $61.4B | $63.9B |
| Operating income | $21.6B | — | — | — | — | — | — | — | — | — |
| Net income | $16.3B | $15.4B | $1.3B | $15.3B | $15.1B | $14.7B | $20.9B | $35.2B | $14.1B | $26.8B |
| EPS (diluted) | $5.70 | $5.48 | $0.47 | $5.61 | $5.63 | $5.51 | $7.81 | $13.72 | $5.79 | $11.03 |
| Free cash flow | $15.0B | $16.1B | $17.8B | $18.5B | $19.9B | $20.2B | $19.8B | $18.2B | $19.8B | $19.7B |
| Buybacks | $7.1B | $5.3B | $6.4B | $5.9B | $6.7B | $3.2B | $3.5B | $5.1B | $2.4B | $6.0B |
| Diluted shares | 2.9B | 2.8B | 2.7B | 2.7B | 2.7B | 2.7B | 2.7B | 2.6B | 2.4B | 2.4B |
Source: SEC filings (10-K XBRL). EPS and share counts are split-adjusted.
What's priced into JNJ?
A reverse DCF asks what growth the current price requires. With an enterprise value of $662.5B and $22.2B of trailing free cash flow, Johnson & Johnson needs to grow free cash flow about 20.7% a year for ten years (fading to 3.0% terminal growth) to earn a 10% annual return. For context, free cash flow grew -0.2% a year over the last five years.
P/E ratio history
Current 23.9x vs. median 21.1x (10th–90th percentile 13.2x–29.9x).
A model, not a forecast or advice. Small changes in assumptions move the answer a lot.
JNJ dividend
- Dividend yield
- 2.03%
- Annual dividend
- $5.36
- Years of increases
- 61
- 5-yr dividend growth
- 5.2%
- per year
- Payout ratio
- 80%
- Payments per year
- 4
Regular dividends per share by calendar year; special dividends excluded. Current year omitted until complete.
JNJ earnings
Next report: January 26, 2027. Johnson & Johnson has beaten EPS estimates 3 quarters in a row.
| Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|
| Oct 13, 2026 | $2.52 | $2.59 | +2.7% |
| Jul 15, 2026 | $2.85 | $2.90 | +1.6% |
| Apr 14, 2026 | $2.68 | $2.70 | +0.8% |
| Jan 21, 2026 | $2.46 | $2.46 | -0.1% |
| Oct 14, 2025 | $2.76 | $2.80 | +1.5% |
| Jul 16, 2025 | $2.68 | $2.77 | +3.2% |
| Apr 15, 2025 | $2.58 | $2.77 | +7.4% |
| Jan 22, 2025 | $2.01 | $2.04 | +1.4% |
Stocks like JNJ
| Name | Today | 1Y | Mkt cap | P/E | |
|---|---|---|---|---|---|
 LLY Eli Lilly and | -2.54% | +56% | $1.1T | 42.7x | Compare |
 MRK Merck & | -1.34% | +72% | $358.4B | 117.2x | Compare |
 PFE Pfizer | -1.28% | +30% | $171.2B | 39.5x | Compare |
 BMY Bristol-Myers Squibb | -2.41% | +47% | $125.6B | 13.5x | Compare |
 ZTS Zoetis | -1.18% | -44% | $33.5B | 13.3x | Compare |
 VTRS Viatris | -2.60% | +81% | $20.7B | — | Compare |
 ABBV AbbVie | +0.16% | +29% | $504.8B | 80.7x | Compare |
 UNH UnitedHealth | -1.62% | +19% | $375.3B | 26.9x | Compare |
JNJ news
- RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) combination demonstrates 77% overall response rate in first-line treatment of patients with advanced head and neck cancer · Oct 25, 2026
- Amgen vs. Johnson & Johnson: Which Healthcare Giant Has the Better Stock to Buy? · Oct 24, 2026
- Johnson & Johnson announces ERLEADA® (apalutamide) treatment before and after surgery reduces risk of recurrence or death by 62% versus surgery alone in high-risk prostate cancer · Oct 24, 2026
- J&J’s Smith & Nephew Deal Collapsed Over One Executive. Here’s What It Means for the DePuy Spin · Oct 24, 2026
- Sector Update: Healthcare Stocks Fall Late Afternoon · Oct 23, 2026
JNJ stock FAQ
What is JNJ's market cap?
Johnson & Johnson's market capitalization is $635.07 billion as of October 23, 2026, ranking 18th in the S&P 500.
What is JNJ's P/E ratio?
JNJ trades at a trailing price-to-earnings ratio of 40.0x and a forward P/E of 22.7x. Its median P/E over the period we track is 21.1x.
Does JNJ pay a dividend?
Yes. Johnson & Johnson pays $5.36 per share a year, a 2.03% yield. It has raised its dividend 61 years in a row. Dividends grew 5.2% a year over the last five years.
How much has JNJ stock returned?
Including reinvested dividends, JNJ returned +40.2% over one year, +13.1% a year over five years, +11.8% a year over ten years through October 23, 2026.
Is JNJ stock overvalued?
At today's price, a reverse discounted cash flow model (10% discount rate, 3% terminal growth) implies Johnson & Johnson must grow free cash flow about 21% a year for the next decade. Its free cash flow fell 0% a year over the last five years. Whether that is achievable decides if the stock is cheap or expensive. This is a model, not advice.
When does JNJ report earnings?
Johnson & Johnson is expected to report earnings on January 26, 2027. It has beaten EPS estimates 3 quarters in a row.
How many employees does Johnson & Johnson have?
Johnson & Johnson has about 138,200 full-time employees, or $718,777 of revenue per employee.
Sources: SEC EDGAR filings, Yahoo Finance market data (delayed), FI Handbook calculations. Last close October 23, 2026. Methodology